370 likes | 507 Views
Compliance With Anticoagulants. Terminology and Definitions. ROCKET AF: Patients Off Study Drug Are at Increased Risk of Stroke and Non-CNS Embolism. Slight Benefit in First Year Post-Trial: No Harm or Benefit Years 2-5+. Features of NOACs. Dosing C onsiderations: Summary.
E N D
ROCKET AF: Patients Off Study Drug Are at Increased Risk of Stroke and Non-CNS Embolism
Slight Benefit in First Year Post-Trial: No Harm or Benefit Years 2-5+
Compliance With OD vs BID Regimens Is Generally Better for Chronic Conditions
Antithrombotic Therapy According to AF Clinical Presentation
Antithrombotic Therapy in AF: Real-World Clinical Characteristics in Japan
J-ROCKET AF: Principal Safety OutcomeMajor or Non-Major Clinically Relevant Bleeding
J-ROCKET AF: Primary Efficacy End PointStroke and Non-CNS Systemic Embolism
AEGEAN Study: Impact of Educational Program on Patient Adherence to Apixaban